CN115666651A - 用tie-2激活剂治疗急性呼吸窘迫综合征的方法 - Google Patents

用tie-2激活剂治疗急性呼吸窘迫综合征的方法 Download PDF

Info

Publication number
CN115666651A
CN115666651A CN202180035947.4A CN202180035947A CN115666651A CN 115666651 A CN115666651 A CN 115666651A CN 202180035947 A CN202180035947 A CN 202180035947A CN 115666651 A CN115666651 A CN 115666651A
Authority
CN
China
Prior art keywords
administration
subject
group
substituted
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180035947.4A
Other languages
English (en)
Chinese (zh)
Inventor
K·彼得斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viewpoint Pharmaceutical Co
Original Assignee
Viewpoint Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viewpoint Pharmaceutical Co filed Critical Viewpoint Pharmaceutical Co
Publication of CN115666651A publication Critical patent/CN115666651A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180035947.4A 2020-05-21 2021-05-20 用tie-2激活剂治疗急性呼吸窘迫综合征的方法 Pending CN115666651A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063028317P 2020-05-21 2020-05-21
US63/028,317 2020-05-21
PCT/US2021/033495 WO2021236985A1 (en) 2020-05-21 2021-05-20 Methods of treating acute respiratory distress syndrome with activators of tie-2

Publications (1)

Publication Number Publication Date
CN115666651A true CN115666651A (zh) 2023-01-31

Family

ID=78707586

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180035947.4A Pending CN115666651A (zh) 2020-05-21 2021-05-20 用tie-2激活剂治疗急性呼吸窘迫综合征的方法

Country Status (7)

Country Link
US (1) US12544362B2 (https=)
EP (1) EP4153237A4 (https=)
JP (1) JP7783834B2 (https=)
CN (1) CN115666651A (https=)
AU (1) AU2021275224A1 (https=)
CA (1) CA3177415A1 (https=)
WO (1) WO2021236985A1 (https=)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2195958C1 (ru) * 2002-02-19 2003-01-10 Центральный научно-исследовательский институт туберкулеза РАМН Способ лечения синдрома острого повреждения легких после расширенных оперативных вмешательств
WO2005034929A2 (en) * 2003-10-10 2005-04-21 Fibrogen, Inc. Tissue remodeling and vascularization
US20070065433A1 (en) * 2003-02-21 2007-03-22 Mollnes Tom E Methods and compositions for the treatment of meconium aspiration syndrome
WO2007084136A2 (en) * 2006-01-23 2007-07-26 Ony, Inc. Treatment of acute respiratory distress syndrome
US20140179693A1 (en) * 2009-01-12 2014-06-26 Robert Shalwitz Methods for treating vascular leak syndrome
US20160058828A1 (en) * 2013-04-11 2016-03-03 Sunnybrook Research Institute Methods, uses and compositions of tie2 agonists
CN106456666A (zh) * 2014-01-10 2017-02-22 Ino治疗有限责任公司 使用吸入性一氧化氮气体来治疗儿童的急性呼吸窘迫综合征的方法
WO2017100796A1 (en) * 2015-12-11 2017-06-15 SINACA, Academia Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2385763T3 (en) * 2009-01-12 2018-07-16 Aerpio Therapeutics Inc METHODS OF TREATING VASCULAR LEAK SYNDROME
CA3137138A1 (en) * 2019-04-18 2020-10-22 EyePoint Pharmaceuticals, Inc. Methods of treating hypertension with activators of tie-2

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2195958C1 (ru) * 2002-02-19 2003-01-10 Центральный научно-исследовательский институт туберкулеза РАМН Способ лечения синдрома острого повреждения легких после расширенных оперативных вмешательств
US20070065433A1 (en) * 2003-02-21 2007-03-22 Mollnes Tom E Methods and compositions for the treatment of meconium aspiration syndrome
WO2005034929A2 (en) * 2003-10-10 2005-04-21 Fibrogen, Inc. Tissue remodeling and vascularization
WO2007084136A2 (en) * 2006-01-23 2007-07-26 Ony, Inc. Treatment of acute respiratory distress syndrome
US20140179693A1 (en) * 2009-01-12 2014-06-26 Robert Shalwitz Methods for treating vascular leak syndrome
US20160058828A1 (en) * 2013-04-11 2016-03-03 Sunnybrook Research Institute Methods, uses and compositions of tie2 agonists
CN106456666A (zh) * 2014-01-10 2017-02-22 Ino治疗有限责任公司 使用吸入性一氧化氮气体来治疗儿童的急性呼吸窘迫综合征的方法
WO2017100796A1 (en) * 2015-12-11 2017-06-15 SINACA, Academia Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PAN LIU等: "New Soluble Angiopoietin Analog of C4BP-ANG1 Prevents Pathological Vascular Leakage", 1 April 2020 (2020-04-01), pages 1 - 15, XP055751906, DOI: 10.1101/2020.03.30.016147 *
SASCHA DAVID等: "Effects of a synthetic PEG-ylated Tie-2 agonist peptide on endotoxemic lung injury and mortality", AM J PHYSIOL LUNG CELL MOL PHYSIOL, vol. 300, 18 March 2011 (2011-03-18), pages 1 - 2 *
XIAOGUANG WANG等: "Sustained improvement of gas exchange and lung mechanics by vaporized perfluorocarbon inhalation in piglet acute lung injury model", THE CLINICAL RESPIRATORY JOURNAL, vol. 8, no. 2, 13 September 2013 (2013-09-13), pages 160 - 166, XP055874891, DOI: 10.1111/crj.12053 *
麦振华: "血管生成素-1 、2 在脓毒症和急性肺损伤/急性呼吸窘迫综合征发生及发展过程中的作用", 广东医学院学报, vol. 29, no. 2, 30 April 2011 (2011-04-30), pages 203 - 206 *

Also Published As

Publication number Publication date
EP4153237A1 (en) 2023-03-29
WO2021236985A1 (en) 2021-11-25
JP7783834B2 (ja) 2025-12-10
EP4153237A4 (en) 2024-07-03
US20240299367A1 (en) 2024-09-12
CA3177415A1 (en) 2021-11-25
AU2021275224A1 (en) 2022-10-13
JP2023526790A (ja) 2023-06-23
US12544362B2 (en) 2026-02-10

Similar Documents

Publication Publication Date Title
US11045434B1 (en) Niclosamide formulations for treating disease
US12409174B2 (en) Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases
US12551469B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
US20160317527A1 (en) Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof
IL296909A (en) Formulation
US11701355B2 (en) Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
US20230129866A1 (en) Methods of treating respiratory disease with deupirfenidone
JP2021519764A (ja) 線維性疾患を処置する方法
US20200352914A1 (en) Methods of treating hypertension with activators of tie-2
JP7783834B2 (ja) Ｔｉｅ－２の活性化物質による急性呼吸窮迫症候群の処置方法
JP2023553290A (ja) 慢性閉塞性肺疾患、喘息、肺炎、気管支炎、嚢胞性線維症、肺水腫、間質性肺疾患、サルコイドーシス、特発性肺胞線維症、急性呼吸窮迫症候群、および肺動脈性肺高血圧症を治療するための方法および組成物
US20250025450A1 (en) Methods of treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases and disorders with deupirfenidone
US20260041656A1 (en) Treating pulmonary hypertension based on novel biomarker
EP4153310B1 (en) Bbeta-15-42 for the treatment of viral endothelitis
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
US20250114340A1 (en) Methods of treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases and disorders with deupirfenidone
US20020115661A1 (en) Method for treating chronic obstructive pulmonary disease
WO2022132777A1 (en) Methods and compositions for hyperinflammatory syndrome and thrombophilia associated with covid-19
HK40063597A (en) Methods of treating hypertension with activators of tie-2
JP2004307351A (ja) 慢性閉塞性肺疾患治療薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination